Developer docs
API playgroundTry for free, no card

Search company profiles

Sanguine

Full company profile

uuid0000fj3

Namestring
Sanguine
Legal namestring
Sanguine Biosciences Inc.
Websiteurl
sanguinebio.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Sanguine Biosciences Inc. (dba Sanguine Bio) is a private biospecimen procurement platform founded in 2010 and headquartered in San Diego, California, with additional operations in Woburn, Massachusetts (kitting/processing) and Los Angeles, California (apheresis collection). The company operates a direct-to-donor model that recruits and collects human biological samples from a verified community of 70,000+ donors across 100+ disease conditions, bypassing traditional biobank intermediaries. Its catalog spans 979 SKUs across blood-derived products (whole blood, PBMC, plasma, serum, leukopaks, including a GMP-grade line), isolated immune cell populations (CD3+, CD4+, CD8+ T cells, CD19+ B cells, CD56+ NK cells, CD34+ stem cells, cord blood products), and an expanding tissue portfolio (skin punch biopsies, synovial fluid, cerebrospinal fluid).

Sanguine's underlying platform integrates electronic medical records, lab results, and patient-reported outcomes with each sample, and it operates under IRB-approved protocols with 50+ advocacy partnerships (e.g., Lupus LA, ASHA, VF, FSR, IPPF, MPPRN) providing preferential donor access for rare autoimmune and inflammatory diseases. The company monetizes through one-time unit-priced e-commerce sales for in-stock biospecimens (ranging from roughly $132 for healthy serum to $7,140+ for disease-state leukopaks), quote-based prospective custom collections for studies with specific inclusion/exclusion criteria, and bundled lab services (sample processing, cellular analysis, sample testing). GTM is hybrid: a self-serve e-commerce storefront serving mid-market researchers and a consultative enterprise sales motion for custom, longitudinal, and GMP-grade programs.

The company has completed 2,000+ studies with a stated 93% on-spec delivery rate and supports research customers across pharmaceutical/biotech drug discovery, academic medical centers, and CROs. Financing history includes a 2013 seed round, a 2014 Series A of $4M led by Seraph Group, a 2019 NSF grant of $224,981, undisclosed rounds in 2022 and 2023 (BroadOak Capital Partners), and a $10M credit facility from Catalio Capital Management in October 2023. Recent strategic emphasis is on expanding into cell and gene therapy supply (GMP leukopaks, apheresis capacity) and adjacent tissue-based research samples.

Short descriptiontext

Sanguine Biosciences is a direct-to-donor biospecimen procurement platform serving pharmaceutical, biotech, academic, and CRO researchers. It supplies blood-derived, immune cell, and tissue samples with integrated EMR and patient-reported outcome data from a 70,000+ donor community.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human biospecimen procurement, biomedical research samples, clinical biospecimen supply, direct-to-donor biospecimens, research sample collection services
Industry2 codes
PRIMARYHLAGACAJ
Clinical Trial Sample Collection & Site Phlebotomy Services
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biospecimen Procurement & Research Sample Supply
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biospecimen Product Sales
TypeOne Time License
Description

One-time purchase of human biospecimens including PBMC, serum, plasma, whole blood, leukopaks, and specialized samples like synovial fluid and skin punch biopsies. Products sold in various formats (fresh, frozen, cryopreserved) with prices ranging from approximately $132 for serum to $7,140+ for disease-specific leukopaks.

sanguinebio.com
2Prospective Custom Collections
TypeOne Time License
Description

Custom collection services where Sanguine recruits donors meeting specific inclusion/exclusion criteria for prospective studies, typically with longer lead times and quote-based pricing.

sanguinebio.com
3Lab Services
TypeProfessional Services
Description

Additional services including sample processing, cellular analysis, and sample testing capabilities that can be bundled with biospecimen purchases.

sanguinebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1In-Stock Inventory Products with standard per-unit pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Starting prices: Healthy Leukopak $2,534, Healthy Serum $132, CD19+ B Cells $1,000, CD3+ T Cells $1,500, CD56+ NK Cells $975. Ships in 2 business days for in-stock items. 10% discount applies.

sanguinebio.com
2Custom/Prospective Collection products with quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Delivery time depends on project requirements. Custom collections require specific I/E criteria and typically start within 2 weeks of agreement. Pricing determined per project.

sanguinebio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sanguine sells human biospecimens (PBMC, serum, plasma, whole blood, leukopaks, isolated immune cell populations, and tissue fluids such as synovial fluid, cerebrospinal fluid, and skin punch biopsies) directly to biomedical researchers through an e-commerce storefront and custom enterprise quoting. The company pairs every sample with linked Electronic Medical Records and Patient-Reported Outcomes data and offers prospective custom collections, lab processing, cellular analysis, and sample testing as bundled services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 93% of samples delivered according to study specifications
+2 more records
Product overview1 text field

Sanguine Biosciences operates a direct-to-donor biospecimen procurement platform providing human biological samples for research. The core product portfolio centers on blood-derived products including Whole Blood, PBMC, Plasma, Serum, Leukopak, GMP Leukopak, and various isolated immune cell populations (CD3+, CD4+, CD8+ T cells, CD19+ B cells, CD56+ NK cells, CD34+ stem cells, and cord blood products). The company expanded into tissue samples with Skin Punch Biopsy, Synovial Fluid, and Cerebrospinal Fluid offerings. Services include Prospective Biospecimen Collection enabling custom inclusion/exclusion criteria and longitudinal studies, OnSite and Community Access collection programs, and Lab Services for processing, cellular analysis, and testing. The platform integrates comprehensive donor data including Electronic Medical Records and Patient-Reported Outcomes. With access to over 70,000 donors across 150+ disease conditions and 50+ advocacy partnerships, the company operates collection facilities in San Diego (HQ), Woburn, MA, and Los Angeles, CA.

Product and service22 records
1PBMC (Peripheral Blood Mononuclear Cells)
CategoryBiospecimen - Blood Derived
Description

Cryopreserved or fresh human peripheral blood mononuclear cells isolated from whole blood, available in cell counts from 5x10^6 to 4x10^9 cells per vial or in bulk format, for immunology, cell therapy, and translational research.

2Whole Blood
CategoryBiospecimen - Blood Derived
Description

Human whole blood samples collected from healthy donors and patients with various disease conditions, available in volumes from 20mL to 100mL in fresh or frozen format, for downstream isolation and analysis.

3Plasma
CategoryBiospecimen - Blood Derived
Description

Human blood plasma samples collected via standard phlebotomy or apheresis (up to 150mL), available frozen or cryopreserved in 1mL to 60mL volumes, for biomarker, therapeutic, and analytical studies.

4Serum
CategoryBiospecimen - Blood Derived
Description

Human blood serum samples processed from whole blood, available frozen, cryopreserved, or fresh in 1mL to 60mL volumes, for diagnostic, biomarker, and disease-state research.

5Leukopak
CategoryBiospecimen - Blood Derived
Description

Concentrated white blood cell products collected via apheresis, available in full or half bag sizes in cryopreserved or fresh format, for immunotherapy and cell therapy research applications.

6GMP Leukopak
CategoryBiospecimen - GMP / Clinical Grade
Description

Good Manufacturing Practice (GMP) compliant leukopak products for clinical and commercial cell therapy manufacturing, currently offered for healthy donors.

7CD3+ T Cells
CategoryBiospecimen - Isolated Immune Cells
Description

Isolated CD3+ T cell populations from peripheral blood for immunotherapy and immunology research.

8CD4+ T Cells
CategoryBiospecimen - Isolated Immune Cells
Description

Isolated CD4+ helper T cell populations for immunology and vaccine research.

9CD8+ T Cells
CategoryBiospecimen - Isolated Immune Cells
Description

Isolated CD8+ cytotoxic T cell populations for cancer immunotherapy research.

10CD19+ B Cells
CategoryBiospecimen - Isolated Immune Cells
Description

Isolated CD19+ B cell populations for antibody therapy and immunology research.

11CD56+ NK Cells
CategoryBiospecimen - Isolated Immune Cells
Description

Isolated CD56+ natural killer cell populations for cancer immunotherapy and innate immunity research.

12CD34+ Cells
CategoryBiospecimen - Stem Cells
Description

Isolated CD34+ hematopoietic stem and progenitor cells for regenerative medicine and cell therapy research.

13Cord Blood
CategoryBiospecimen - Stem Cells
Description

Whole cord blood samples containing hematopoietic stem cells for stem cell research and transplantation studies.

14Skin Punch Biopsy
CategoryBiospecimen - Tissue
Description

Human skin punch biopsy samples in 2mm or 3mm sizes, available fresh or frozen, for dermatology and autoimmune disease research.

15Synovial Fluid
CategoryBiospecimen - Tissue Fluid
Description

Human synovial fluid samples collected from joints, available fresh or frozen in 1mL volumes, for rheumatology and autoimmune research.

16Cerebrospinal Fluid
CategoryBiospecimen - Tissue Fluid
Description

Human cerebrospinal fluid samples for neurological and neurodegenerative disease research.

17Prospective Biospecimen Collection Services
CategoryCustom Collection Service
Description

Custom biospecimen collection services enabling researchers to specify inclusion/exclusion criteria, conduct longitudinal studies, and access recallable participants with prospective study design.

18Sample Processing Services
CategoryLab Services
Description

Laboratory processing services for collected biospecimens including cell isolation and preservation, bundled with biospecimen purchases.

19Cellular Analysis Services
CategoryLab Services
Description

Cell analysis laboratory services including characterization and functional testing of cells, offered as a value-add with biospecimen orders.

20Sample Testing Services
CategoryLab Services
Description

Testing services for biospecimens including infectious disease screening and quality control prior to delivery to researchers.

21Electronic Medical Records (EMR) Data Access
CategoryDonor Data Services
Description

Access to electronic medical and health records data for matched biospecimens to enhance research value and enable clinical correlation studies.

22Patient-Reported Outcomes (PRO) and Surveys
CategoryDonor Data Services
Description

Patient-reported outcome data collection via surveys and questionnaires to provide comprehensive research datasets linked to biospecimens.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Lupus LA
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy partnership providing access to lupus patient community for biospecimen recruitment and supporting lupus research initiatives.

sanguinebio.com
2American Sjögren's Foundation (ASHA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Advocacy partnership supporting Sjögren's syndrome research through patient community access and biospecimen recruitment collaboration.

sanguinebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Vasculitis Foundation to support research into vasculitis diseases through patient engagement and sample collection programs.

4Foundation for Scleroderma Research (FSR)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Advocacy partnership supporting scleroderma research through community access and biospecimen programs for scleroderma patients.

sanguinebio.com
5International Pemphigus and Pemphigoid Foundation (IPPF)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with IPPF supporting pemphigus and pemphigoid research through patient advocacy network and biospecimen collection collaboration.

sanguinebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership supporting myositis research through patient engagement and collaborative biospecimen programs.

7Various US Clinical Partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnerships across the United States for sample collection and clinical data, enabling synovial fluid and skin punch biopsy offerings for autoimmune, dermatology, rheumatology, and inflammation research.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Operates a marketplace platform connecting researchers with biospecimen suppliers and biobanks. Directly comparable to Sanguine's e-commerce/marketplace model for human biospecimens serving pharma, biotech, and academic researchers.

TypeDirect peer
Description

One of the largest commercial suppliers of human biospecimens and tissue samples to the research and diagnostic industry. Directly comparable to Sanguine's catalog of blood, plasma, serum, and disease-state samples for pharma/biotech research customers.

TypeDirect peer
Description

Global biospecimen provider offering tissue, blood, and cellular products with integrated lab services for research and clinical diagnostics. Comparable as a vertically integrated biospecimen + lab services competitor in oncology, autoimmune, and rare disease samples.

TypeDirect peer
Description

Specialty human biospecimen provider focused on disease-state tissue and biofluids for pharmaceutical and biotech research. Comparable to Sanguine in prospective collection, disease-state biospecimens, and clinical sample procurement for translational research.

TypeDirect peer
Description

Supplier of biospecimens, FFPE tissues, and molecular derivatives for biomedical research. Comparable to Sanguine in catalog biospecimen sales (tissue, blood products) and disease-state sample offerings for research customers.

TypeDirect peer
Description

Provider of human tissue samples and biofluids with clinical data for pharmaceutical research and biomarker discovery. Comparable to Sanguine in custom prospective collections, matched clinical data, and disease-state sample offerings.

TypeBroad incumbent
Description

Broader life science tools provider of primary cells, cell culture media, and reagents for research. Overlaps with Sanguine's isolated immune cell products (CD3+, CD4+, CD8+, CD19+, NK cells) and serves similar pharma/biotech researchers, though as part of a wider portfolio.

TypeBroad incumbent
Description

Global CDMO and bioscience solutions provider offering primary cells, media, and biospecimens through its Bioscience segment. Comparable as a larger incumbent supplying leukopaks, primary cells, and cell therapy starting materials to research and clinical customers.

TypeBroad incumbent
Description

Provider of biospecimen, biomarker, and translational research services to pharma/biotech. Comparable to Sanguine's higher-end prospective collection and lab services (cellular analysis, sample testing) bundled with biospecimens for clinical research customers.

10Boca Biolistics
TypeEmerging player
Description

Specialty biospecimen provider offering disease-state and normal human samples with donor data for research. Comparable to Sanguine in catalog biospecimen sales and prospective collection services, though with a smaller portfolio and more limited apheresis infrastructure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanguine

Biospecimen Procurement & Research Sample Supplysanguinebio.com

Sanguine Biosciences is a direct-to-donor biospecimen procurement platform serving pharmaceutical, biotech, academic, and CRO researchers. It supplies blood-derived, immune cell, and tissue samples with integrated EMR and patient-reported outcome data from a 70,000+ donor community.

What Sanguine does

Sanguine Biosciences Inc. (dba Sanguine Bio) is a private biospecimen procurement platform founded in 2010 and headquartered in San Diego, California, with additional operations in Woburn, Massachusetts (kitting/processing) and Los Angeles, California (apheresis collection). The company operates a direct-to-donor model that recruits and collects human biological samples from a verified community of 70,000+ donors across 100+ disease conditions, bypassing traditional biobank intermediaries. Its catalog spans 979 SKUs across blood-derived products (whole blood, PBMC, plasma, serum, leukopaks, including a GMP-grade line), isolated immune cell populations (CD3+, CD4+, CD8+ T cells, CD19+ B cells, CD56+ NK cells, CD34+ stem cells, cord blood products), and an expanding tissue portfolio (skin punch biopsies, synovial fluid, cerebrospinal fluid).

Sanguine's underlying platform integrates electronic medical records, lab results, and patient-reported outcomes with each sample, and it operates under IRB-approved protocols with 50+ advocacy partnerships (e.g., Lupus LA, ASHA, VF, FSR, IPPF, MPPRN) providing preferential donor access for rare autoimmune and inflammatory diseases. The company monetizes through one-time unit-priced e-commerce sales for in-stock biospecimens (ranging from roughly $132 for healthy serum to $7,140+ for disease-state leukopaks), quote-based prospective custom collections for studies with specific inclusion/exclusion criteria, and bundled lab services (sample processing, cellular analysis, sample testing). GTM is hybrid: a self-serve e-commerce storefront serving mid-market researchers and a consultative enterprise sales motion for custom, longitudinal, and GMP-grade programs.

The company has completed 2,000+ studies with a stated 93% on-spec delivery rate and supports research customers across pharmaceutical/biotech drug discovery, academic medical centers, and CROs. Financing history includes a 2013 seed round, a 2014 Series A of $4M led by Seraph Group, a 2019 NSF grant of $224,981, undisclosed rounds in 2022 and 2023 (BroadOak Capital Partners), and a $10M credit facility from Catalio Capital Management in October 2023. Recent strategic emphasis is on expanding into cell and gene therapy supply (GMP leukopaks, apheresis capacity) and adjacent tissue-based research samples.

Sanguine firmographics

Firmographics
Name
Sanguine
Legal name
Sanguine Biosciences Inc.
Website
https://sanguinebio.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
101–250 employees
Short description
Sanguine Biosciences is a direct-to-donor biospecimen procurement platform serving pharmaceutical, biotech, academic, and CRO researchers. It supplies blood-derived, immune cell, and tissue samples with integrated EMR and patient-reported outcome data from a 70,000+ donor community.
Ownership category
akta.pro rank

Sanguine industry classification

Industry
Product category
Biospecimen Procurement & Research Sample Supply
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAJ
Clinical Trial Sample Collection & Site Phlebotomy Services
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Human biospecimen procurement
  • Biomedical research samples
  • Clinical biospecimen supply
  • Direct-to-donor biospecimens
  • Research sample collection services

Where Sanguine is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Sanguine business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Biospecimen Product Sales: One-time purchase of human biospecimens including PBMC, serum, plasma, whole blood, leukopaks, and specialized samples like synovial fluid and skin punch biopsies. Products sold in various formats (fresh, frozen, cryopreserved) with prices ranging from approximately $132 for serum to $7,140+ for disease-specific leukopaks.
  2. Prospective Custom Collections: Custom collection services where Sanguine recruits donors meeting specific inclusion/exclusion criteria for prospective studies, typically with longer lead times and quote-based pricing.
  3. Lab Services: Additional services including sample processing, cellular analysis, and sample testing capabilities that can be bundled with biospecimen purchases.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goIn-Stock Inventory Products with standard per-unit pricing
OtherMulti-year contractCustom/Prospective Collection products with quote-based pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Sanguine product offering

Product offering

Core offering

Sanguine sells human biospecimens (PBMC, serum, plasma, whole blood, leukopaks, isolated immune cell populations, and tissue fluids such as synovial fluid, cerebrospinal fluid, and skin punch biopsies) directly to biomedical researchers through an e-commerce storefront and custom enterprise quoting. The company pairs every sample with linked Electronic Medical Records and Patient-Reported Outcomes data and offers prospective custom collections, lab processing, cellular analysis, and sample testing as bundled services.

Product overview

Sanguine Biosciences operates a direct-to-donor biospecimen procurement platform providing human biological samples for research. The core product portfolio centers on blood-derived products including Whole Blood, PBMC, Plasma, Serum, Leukopak, GMP Leukopak, and various isolated immune cell populations (CD3+, CD4+, CD8+ T cells, CD19+ B cells, CD56+ NK cells, CD34+ stem cells, and cord blood products). The company expanded into tissue samples with Skin Punch Biopsy, Synovial Fluid, and Cerebrospinal Fluid offerings. Services include Prospective Biospecimen Collection enabling custom inclusion/exclusion criteria and longitudinal studies, OnSite and Community Access collection programs, and Lab Services for processing, cellular analysis, and testing. The platform integrates comprehensive donor data including Electronic Medical Records and Patient-Reported Outcomes. With access to over 70,000 donors across 150+ disease conditions and 50+ advocacy partnerships, the company operates collection facilities in San Diego (HQ), Woburn, MA, and Los Angeles, CA.

Differentiator

Problem solved

Functional benefit

Products and services

  • PBMC (Peripheral Blood Mononuclear Cells) Cryopreserved or fresh human peripheral blood mononuclear cells isolated from whole blood, available in cell counts from 5x10^6 to 4x10^9 cells per vial or in bulk format, for immunology, cell therapy, and translational research.
  • Whole Blood Human whole blood samples collected from healthy donors and patients with various disease conditions, available in volumes from 20mL to 100mL in fresh or frozen format, for downstream isolation and analysis.
  • Plasma Human blood plasma samples collected via standard phlebotomy or apheresis (up to 150mL), available frozen or cryopreserved in 1mL to 60mL volumes, for biomarker, therapeutic, and analytical studies.
  • Serum Human blood serum samples processed from whole blood, available frozen, cryopreserved, or fresh in 1mL to 60mL volumes, for diagnostic, biomarker, and disease-state research.
  • Leukopak Concentrated white blood cell products collected via apheresis, available in full or half bag sizes in cryopreserved or fresh format, for immunotherapy and cell therapy research applications.
  • GMP Leukopak Good Manufacturing Practice (GMP) compliant leukopak products for clinical and commercial cell therapy manufacturing, currently offered for healthy donors.
  • CD3+ T Cells Isolated CD3+ T cell populations from peripheral blood for immunotherapy and immunology research.
  • CD4+ T Cells Isolated CD4+ helper T cell populations for immunology and vaccine research.
  • CD8+ T Cells Isolated CD8+ cytotoxic T cell populations for cancer immunotherapy research.
  • CD19+ B Cells Isolated CD19+ B cell populations for antibody therapy and immunology research.
  • CD56+ NK Cells Isolated CD56+ natural killer cell populations for cancer immunotherapy and innate immunity research.
  • CD34+ Cells Isolated CD34+ hematopoietic stem and progenitor cells for regenerative medicine and cell therapy research.
  • Cord Blood Whole cord blood samples containing hematopoietic stem cells for stem cell research and transplantation studies.
  • Skin Punch Biopsy Human skin punch biopsy samples in 2mm or 3mm sizes, available fresh or frozen, for dermatology and autoimmune disease research.
  • Synovial Fluid Human synovial fluid samples collected from joints, available fresh or frozen in 1mL volumes, for rheumatology and autoimmune research.
  • Cerebrospinal Fluid Human cerebrospinal fluid samples for neurological and neurodegenerative disease research.
  • Prospective Biospecimen Collection Services Custom biospecimen collection services enabling researchers to specify inclusion/exclusion criteria, conduct longitudinal studies, and access recallable participants with prospective study design.
  • Sample Processing Services Laboratory processing services for collected biospecimens including cell isolation and preservation, bundled with biospecimen purchases.
  • Cellular Analysis Services Cell analysis laboratory services including characterization and functional testing of cells, offered as a value-add with biospecimen orders.
  • Sample Testing Services Testing services for biospecimens including infectious disease screening and quality control prior to delivery to researchers.
  • Electronic Medical Records (EMR) Data Access Access to electronic medical and health records data for matched biospecimens to enhance research value and enable clinical correlation studies.
  • Patient-Reported Outcomes (PRO) and Surveys Patient-reported outcome data collection via surveys and questionnaires to provide comprehensive research datasets linked to biospecimens.

Quantifiable outcome

  • 93% of samples delivered according to study specifications
  • +2 more outcomes

Companies that use Sanguine

Customer profile

Segments3 records

Ideal customer profiles3 records

Sanguine technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sanguine partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Lupus LAcoreStrategic or Co-development PartnerPatient advocacy partnership providing access to lupus patient community for biospecimen recruitment and supporting lupus research initiatives.
  • American Sjögren's Foundation (ASHA)coreStrategic or Co-development PartnerAdvocacy partnership supporting Sjögren's syndrome research through patient community access and biospecimen recruitment collaboration.
  • Vasculitis Foundation (VF)coreStrategic or Co-development PartnerPartnership with Vasculitis Foundation to support research into vasculitis diseases through patient engagement and sample collection programs.
  • Foundation for Scleroderma Research (FSR)coreStrategic or Co-development PartnerAdvocacy partnership supporting scleroderma research through community access and biospecimen programs for scleroderma patients.
  • International Pemphigus and Pemphigoid Foundation (IPPF)coreStrategic or Co-development PartnerPartnership with IPPF supporting pemphigus and pemphigoid research through patient advocacy network and biospecimen collection collaboration.
  • Myositis Patient-Partnered Research Network (MPPRN)coreStrategic or Co-development PartnerPartnership supporting myositis research through patient engagement and collaborative biospecimen programs.
  • Various US Clinical PartnersminorStrategic or Co-development PartnerPartnerships across the United States for sample collection and clinical data, enabling synovial fluid and skin punch biopsy offerings for autoimmune, dermatology, rheumatology, and inflammation research.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Sanguine competitors and assessment

Company assessment

Direct peers

  • iSpecimen: Operates a marketplace platform connecting researchers with biospecimen suppliers and biobanks. Directly comparable to Sanguine's e-commerce/marketplace model for human biospecimens serving pharma, biotech, and academic researchers.
  • BioIVT: One of the largest commercial suppliers of human biospecimens and tissue samples to the research and diagnostic industry. Directly comparable to Sanguine's catalog of blood, plasma, serum, and disease-state samples for pharma/biotech research customers.
  • Discovery Life Sciences: Global biospecimen provider offering tissue, blood, and cellular products with integrated lab services for research and clinical diagnostics. Comparable as a vertically integrated biospecimen + lab services competitor in oncology, autoimmune, and rare disease samples.
  • Cureline: Specialty human biospecimen provider focused on disease-state tissue and biofluids for pharmaceutical and biotech research. Comparable to Sanguine in prospective collection, disease-state biospecimens, and clinical sample procurement for translational research.
  • BioChain Institute: Supplier of biospecimens, FFPE tissues, and molecular derivatives for biomedical research. Comparable to Sanguine in catalog biospecimen sales (tissue, blood products) and disease-state sample offerings for research customers.
  • ProteoGenex: Provider of human tissue samples and biofluids with clinical data for pharmaceutical research and biomarker discovery. Comparable to Sanguine in custom prospective collections, matched clinical data, and disease-state sample offerings.

Broad incumbents

  • Stemcell Technologies: Broader life science tools provider of primary cells, cell culture media, and reagents for research. Overlaps with Sanguine's isolated immune cell products (CD3+, CD4+, CD8+, CD19+, NK cells) and serves similar pharma/biotech researchers, though as part of a wider portfolio.
  • Lonza Bioscience Solutions: Global CDMO and bioscience solutions provider offering primary cells, media, and biospecimens through its Bioscience segment. Comparable as a larger incumbent supplying leukopaks, primary cells, and cell therapy starting materials to research and clinical customers.
  • Precision Medicine Group: Provider of biospecimen, biomarker, and translational research services to pharma/biotech. Comparable to Sanguine's higher-end prospective collection and lab services (cellular analysis, sample testing) bundled with biospecimens for clinical research customers.

Emerging players

  • Boca Biolistics: Specialty biospecimen provider offering disease-state and normal human samples with donor data for research. Comparable to Sanguine in catalog biospecimen sales and prospective collection services, though with a smaller portfolio and more limited apheresis infrastructure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Sanguine social profiles

Digital presence

Sanguine compliance and trust

Trust signal

Compliance1 record

Sanguine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanguine leadership team

Management profile

Number of profiles

Profiles6 records

Sanguine funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanguine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanguine

What does Sanguine do?

Sanguine sells human biospecimens (PBMC, serum, plasma, whole blood, leukopaks, isolated immune cell populations, and tissue fluids such as synovial fluid, cerebrospinal fluid, and skin punch biopsies) directly to biomedical researchers through an e-commerce storefront and custom enterprise quoting. The company pairs every sample with linked Electronic Medical Records and Patient-Reported Outcomes data and offers prospective custom collections, lab processing, cellular analysis, and sample testing as bundled services.

Is Sanguine a public or private company?

Sanguine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sanguine founded?

Sanguine was founded in 2010. It employs 101 to 250 people.

Where is Sanguine based?

Sanguine is headquartered in Woburn, United States, in the North America region.

How does Sanguine make money?

Three revenue lines are on record. Biospecimen Product Sales are the primary driver. The others are prospective Custom Collections and lab Services.

Who are Sanguine's main competitors?

Direct peers on record are iSpecimen, BioIVT, Discovery Life Sciences, Cureline, BioChain Institute and ProteoGenex. Broad incumbents are Stemcell Technologies, Lonza Bioscience Solutions and Precision Medicine Group. Boca Biolistics is listed as an emerging player.

Does Sanguine have an API?

No public API is recorded for Sanguine.

What industry is Sanguine in?

Sanguine's product category is Biospecimen Procurement & Research Sample Supply. Its primary akta.pro industry code is HLAGACAJ, Clinical Trial Sample Collection & Site Phlebotomy Services, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebSanguine Partnership Solutions Appoints Jen Kalant as President & Chief Partnerships Officer to Formalize Partnerships-as-a-Service for Growing B2B CompaniesSanguine Partnership Solutions has appointed Jen Kalant as President and Chief Partnerships Officer and launched its Partnerships-as-a-Service model aimed at helping B2B companies develop structured partnership programs. This initiative is designed to provide the necessary frameworks and leadership for businesses that may not have the internal resources to establish effective partnerships. The move reflects a strategic focus on leveraging partnerships as a critical growth driver for small and mid-sized enterprises.PR NewswireSanguine Biosciences Expands Clinical Biospecimen Portfolio With New Synovial Fluid and Skin Punch Biopsy OfferingsSanguine Biosciences announced the expansion of its clinical biospecimen portfolio with two new offerings: synovial fluid and skin punch biopsy collections. These additions are designed to support research into autoimmune, dermatological, and inflammatory disorders by providing high-quality samples paired with comprehensive clinical data from US-based sites.PR NewswireSanguine Expands Oncology Biospecimen Offerings Through Strategic Clinic PartnershipsSanguine Biosciences announced the expansion of its oncology biospecimen offerings through new partnerships with over 20 oncology clinics across the United States. These collaborations enable the company to provide researchers with high-quality, minimally invasive treatment-naive samples and integrated clinical data to accelerate cancer discovery. The initiative aims to support academic institutions and pharmaceutical companies in biomarker discovery and drug development by addressing bottlenecks in sample access.Business Wire BlogSanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com’s Supplier Pre-assessment ProgramSanguine Biosciences completed a VERIF.i on-site assessment from Scientist.com, demonstrating its biospecimen service quality. The company's direct-to-donor model provides ethically procured biospecimens for research, including apheresis products and biorepository services. The assessment aims to build trust with researchers and pharmaceutical companies.Pulse 2.0Sanguine Biosciences: $10 Million Credit Financing Provided By Catalio Capital ManagementSanguine Biosciences secured $10 million in credit financing from Catalio Capital Management to support its apheresis donation center and cell & gene therapy product development. The senior secured term loan includes an initial draw of $6 million with an additional $4 million available at the company's option. This funding aims to facilitate commercial growth and the creation of GMP-grade biospecimens for precision medicine research.Business Wire BlogSanguine Biosciences Announces $10 Million Credit Financing from Catalio Capital Management to Fund Continued GrowthSanguine Biosciences secured a $10 million credit financing facility from Catalio Capital Management to support its growth in the cell and gene therapy sector. The senior secured term loan includes an initial draw of $6 million, with funds designated for developing apheresis-derived products and expanding commercial operations. Additionally, a representative from Catalio will join Sanguine's board as an observer to facilitate the partnership.PR NewswireSANGUINE BIOSCIENCES OPENS NEW APHERESIS DONOR CENTER TO SUPPORT CELL & GENE THERAPY AND TRANSLATIONAL RESEARCH INITIATIVESSanguine Biosciences opened a new apheresis donor center in Los Angeles, California on September 13, 2023, specializing in collecting concentrated white blood cell biospecimens through leukopaks to support cell and gene therapy development programs. The center, partly funded by BroadOak Capital's investment announced earlier this year, expands the company's capacity to serve researchers and grows its donor community of over 70,000 individuals nationwide. The company forecasts opening a second apheresis center in the Boston metropolitan area in 2024 to enable same-day specimen delivery to Boston-area biomedical research teams.BioSpaceSanguine Biosciences Partners With Broadoak Capital Partners to Accelerate Launch of New Products and Services in Support of Cell & Gene Therapy MarketsSanguine Biosciences announced a new investment from BroadOak Capital Partners to expand its laboratory operations, leukapheresis offerings, and patient donor network. The partnership supports Sanguine's apheresis product family and its 60,000+ research-ready patient donor network. The funds will bolster laboratory and apheresis initiatives for cell and gene therapy developers.PR NewswireSANGUINE BIOSCIENCES PARTNERS WITH BROADOAK CAPITAL PARTNERS TO ACCELERATE LAUNCH OF NEW PRODUCTS AND SERVICES IN SUPPORT OF CELL & GENE THERAPY MARKETSSanguine Biosciences announced a new investment from BroadOak Capital Partners to expand its laboratory operations, leukapheresis offerings, and patient donor network. The partnership supports Sanguine's apheresis product family and pre-analytical specimen processing services. The investment aims to accelerate cell and gene therapy development.PR NewswireBGI & Sanguine Join Forces to Increase Speed and Efficiency of Precision Clinical Trial RecruitmentBGI Genomics and Sanguine BioSciences have formed a partnership to develop a combined genomic and clinical data database aimed at improving precision clinical trial recruitment for drug developers. Their first project will enable trial developers to access searchable Whole Genome and Electronic Medical Record data from over 1,000 Rheumatoid Arthritis patients. The collaboration is designed to increase trial cohort homogeneity, reduce risk and cost, and improve likelihood of trial success by allowing developers to select and enroll specific patient populations.